NCT01719809

Brief Summary

This is a prospective, observational, single-center study. Patients with at least 3 months of experience using topical medications for glaucoma and who state that they administer their own eye drops will be recruited. Subjects will be videotaped instilling a sterile artificial eye drop, will be identified at the time of a regularly scheduled exam. If the patient can get a drop onto the eye and also not touch their lids or ocular surface with the eye drop bottle, the subject will be thanked but not enrolled. All other patients who agree to participate will be enrolled. Upon completion of videotaped instillation of an eye drop, each enrolled patient will be shown a video demonstrating an instillation technique and will be given an instructional handout highlighting a proper drop instillation technique. If necessary, an instillation technique will be demonstrated to them by an investigator or trained personnel. A patient will be identified as properly instilling a drop if they satisfy the following criteia: They are able to instill one (and only one) drop to the ocular surface or lower fornix without allowing the bottle touch the adnexa, eyelid, eye lashes or eye. All patients routinely return between 3 and 6 months. At this regularly scheduled visit,the investigator or trained personnel would direct the patient to instill an eye drop into the study eye.Additionally, the short glaucoma self-efficacy questionnaire will be re-administered. All of the video-recordings of participants' eye drop instillation techniques will be reviewed and assessed using a standard checklist. Their ability to administer an eye drop after training will be compared to baseline.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2012

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

October 25, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 1, 2012

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

April 12, 2017

Status Verified

April 1, 2017

Enrollment Period

2.7 years

First QC Date

October 25, 2012

Last Update Submit

April 11, 2017

Conditions

Keywords

GlaucomaEye DropEye Drop TechniqueTrainingInstilling Eye Drops

Outcome Measures

Primary Outcomes (1)

  • Ability to administer an eye drop according to our criteria, as outlined in our study summary.

    6 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Private Ophthalmology Office (Specialty-Glaucoma)

You may qualify if:

  • Patients aged 18 years or older
  • Patients currently using topical ocular antihypertensive medications at the time of enrollment in at least one eye, and who have been using these drops consistently for a period of at least three months prior to enrollment.
  • Patients with primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma, ocular hypertension, normal-tension glaucoma, neovascular glaucoma, uveitic glaucoma and chronic narrow angle glaucoma.
  • Patients CAN be enrolled even if they have co-existing morbidities such as Parkinson's Disease or arthritis

You may not qualify if:

  • Patients who do not instill their own eye drops
  • Patients who are not expected to still be using topical antihypertensive medications at the time of study follow-up
  • Patients with no light perception vision
  • Patients with a history of adverse reaction to artificial tears or any component of artificial tears
  • Patients who have a typical follow-up period of greater than 6 months
  • Patients who have not completed a Humphrey Visual Field C24-2 or C10-2 within 7 months of enrollment or study exit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alan L. Robin, MD, PA

Baltimore, Maryland, 21209, United States

Location

MeSH Terms

Conditions

GlaucomaOcular Hypertension

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Adam C LePosa, OD

    Alan L. Robin, MD, PA

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDIV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Adam C. LePosa, O.D

Study Record Dates

First Submitted

October 25, 2012

First Posted

November 1, 2012

Study Start

October 1, 2012

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

April 12, 2017

Record last verified: 2017-04

Locations